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Neuromedin U (NMU) is a neuropeptide that is expressed in the gastrointestinal tract and 
central nervous system. NMU interacts with two G protein–coupled receptors, NMU-R1 
and NMU-R2. Whereas NMU-R2 localizes predominantly to nerve cells, NMU-R1 is 
expressed in peripheral tissues including lymphocytes and monocytes, suggesting a role of 
NMU in immunoregulation. However, the functions of NMU in peripheral tissues have not 
been clarified. In this study, using NMU-deficient mice, we first demonstrated that NMU 
plays an important role in mast cell-mediated inflammation. Complete Freund’s adjuvant-
induced mast cell degranulation as well as edema and neutrophil infiltration, which occurred 
weakly in mast cell–deficient WBB6F
 
1
 
-
 
W/W
 
v
 
 mice, did not occur in NMU-deficient mice. 
Moreover, intraplantar injection of NMU into paws induced early inflammatory responses 
such as mast cell degranulation, vasodilation, and plasma extravasation in WT mice but 
not in WBB6F
 
1
 
-
 
W/W
 
v
 
 mice. NMU-R1 was highly expressed in primary mast cells, and 
NMU induced Ca
 
2
 
 
 
 mobilization and degranulation in peritoneal mast cells. These data 
indicate that NMU promotes mast cell–mediated inflammation; therefore, NMU receptor 
antagonists could be a novel target for pharmacological inhibition of mast cell–mediated 
inflammatory diseases.
 
Neuromedin U (NMU) is a neuropeptide
originally purified from porcine spinal cord
(1). The first biological activity ascribed to
NMU was smooth muscle contraction of the
uterus, but NMU now has been shown to
reduce food intake and body weight (2),
regulate stress responses (3), and modify ion
transport in the gastrointestinal tract (4). De-
spite extensive study of the actions of this
peptide, its receptors, NMU-R1 and NMU-R2,
have been identified only recently (2). NMU-
R1 and NMU-R2, which share 51% amino
acid identity, both belong to the G protein–
coupled receptor family. Both NMU-R1
and NMU-R2 mobilize intracellular Ca
 
2
 
 
 
stores in response to NMU binding, suggest-
ing that these receptors couple to members
of the G
 
q11
 
 subfamily of G protein (5). NMU-
R2 is expressed in a specific region of the
brain, whereas NMU-R1 is expressed abun-
dantly in various peripheral tissues, with rela-
tively high levels in the small intestine, pancreas,
and stomach. Recent studies have indicated
that NMU has potent pronociceptive effects
acting on NMU-R1 and NMU-R2 expressed
in the spinal cord (6–8).
NMU-R1 is also expressed in spleen and
lymphocytes (9). Recently, NMU was shown
to promote intracellular Ca
 
2
 
 
 
 release and the
secretion of various cytokines in a mouse Th2
cell clone (10). Because NMU has been
shown to be expressed in APCs, including
dendritic cells, monocytes, and B cells (9),
NMU is suggested to be involved in the reg-
ulation of innate and adaptive immunity.
A number of neuropeptides, such as sub-
stance P (SP) and neuropeptide Y, are expressed
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in central and peripheral nerve cells and are known to
activate mast cells directly, which trigger neurogenic in-
flammation and promote further anaphylactic responses
(11–13). Alternately, chemical mediators secreted from ac-
tivated mast cells, such as histamine and serotonin, stimu-
late neural cells. Therefore, mast cells are thought to be an
important interface between the immune and neuro-endo-
crine systems.
In this paper, using NMU-deficient (KO) mice, we
demonstrate that NMU plays an important role in mast cell–
dependent inflammation models such as CFA-induced va-
sodilation and neutrophil infiltration in the paw. Using mast
cell–deficient WBB6F
 
1
 
-
 
W/W
 
v
 
 mice, we also demonstrate
that exogenous NMU injection triggered mast cell–depen-
dent early inflammatory responses. Unlike other neuroin-
flammatory peptides, NMU is expressed abundantly in epi-
dermis and is released by CFA injection. NMU activates
mast cells directly, inducing Ca
 
2
 
 
 
 mobilization and degranu-
lation in vitro. We propose that NMU is an important me-
diator of mast cell–mediated inflammation.
Figure 1. Reduced CFA-induced inflammation in NMU-KO mice. 
(A) Paw swelling, neutrophil infiltration, and localization of mast cells in 
the paws of CFA-treated mice. (a) Hindlegs of WT, NMU-KO, WBB6F1- / , 
-W/Wv, and W/Wv- /  mice photographed 24 h after intraplantar injection 
of CFA or vehicle. (b) Sections of paws removed 3 h after CFA injection were 
stained with H&E. b-2 shows magnified photos of rectangular regions 
in b-1. (c) Localization of skin mast cells stained with TB. Bars, 50  m. 
(B) Time course of the changes in paw diameter after intraplantar injection 
of CFA (n   4 for each time point). (C) Expressions of NMU and NMU-R1 
mRNA determined by RT-PCR of BMMCs and indicated organs derived 
from WT mice. (D) Expressions of NMU, NMU-R1, and the indicated in-
flammatory mediators in the paws of indicated mice before or after intra-
plantar CFA injection. Two different mice were examined at 3 h, from 
which the expression levels were determined by RT-PCR. 
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RESULTS AND DISCUSSION
Suppression of CFA-induced inflammation 
in NMU-deficient mice
 
NMU-KO mice exhibit obesity and reduced nociceptive re-
flexes, which are reflective of the functions of NMU in the ner-
vous system (8,14). Although NMU-R1 is expressed in a vari-
ety of tissues, including the gastrointestinal tracts and immune
cells such as T cells, NK cells, and monocytes (9), the role of
NMU in the periphery has not been clarified. Therefore, we
first compared inflammatory responses using NMU-KO mice.
Intraplantar injection of CFA induced edema, neutrophil
infiltration, and paw swelling in WT C57BL6/J mice (WT
and KO; Fig. 1, A and B). NMU mRNA expression levels
were extremely high in the paws of WT mice, being compa-
rable or even higher than those in the intestine, which has
been thought to be the most abundant source of NMU (Fig.
1 C). In contrast, paw edema and neutrophil infiltration did
not occur in NMU-KO mice 3 h after intraplantar CFA
injection (WT and KO; Fig. 1, A and B). In WT mice,
injection of CFA resulted in a rapid induction of proinflam-
matory cytokines including TNF-
 
 
 
, IL-6, macrophage in-
flammatory protein 2, and leukocyte adhesion molecules,
such as intracellular cell adhesion molecule 1, on the surface
of endothelial cells (WT; Fig. 1 D). Induction of these acute
inflammatory factors, however, did not occur in NMU-KO
mice (KO; Fig. 1 D), indicating that NMU plays a critical
role in the early inflammatory responses induced by CFA.
The early inflammation induced by CFA has been shown
to be mast cell–dependent (15). Indeed, WBB6F
 
1
 
-
 
W/W
 
v
 
 mice
in which mast cells are deficient did not exhibit any paw swell-
ing, infiltration of neutrophils, or the induction of proinflam-
matory cytokines and intracellular cell adhesion molecule 1 by
CFA injection, whereas control WBB6F
 
1
 
-
 
 
 
/
 
 
 
 mice devel-
oped inflammation in a manner similar to WT mice (WBB6F
 
1
 
-
 
 
 
/
 
 
 
 and –
 
W/W
 
v
 
; Fig. 1, A, B, and D). BM-derived mast cells
(BMMCs) expressed relatively high levels of NMU-R1
mRNA, compared with BM or spleen cells (Fig. 1 C). Recon-
stitution of skin mast cells in WBB6F
 
1
 
-
 
W/W
 
v
 
 mice with BM-
MCs from -
 
 
 
/
 
 
 
 mice (
 
W/W
 
v
 
 -
 
 
 
/
 
 
 
) by adoptive transfer re-
stored the CFA-induced inflammatory responses (
 
W/W
 
v
 
 -
 
 
 
/
 
 
 
;
Fig. 1, A and B), confirming that the early phase of CFA-induced
inflammation is dependent on mast cells.
The number and degranulation of skin mast cells were
confirmed by toluidine blue (TB) staining. The total numbers
of mast cells were not significantly different in the paws of
WT, NMU-KO, and WBB6F
 
1
 
-
 
 
 
/
 
 
 
 mice (Fig. S1 A, avail-
able at http://www.jem.org/cgi/content/full/jem.20050248/
DC1), suggesting that the NMU deficiency did not alter mast
cell development in NMU-KO mice. However, intense de-
granulation of mast cells was observed 3 h after CFA applica-
tion in the paws of WT and WBB6F
 
1
 
-
 
 
 
/
 
 
 
 mice but not in
those of NMU-KO mice (Fig. S1 B). These data suggest a
strong connection between NMU and the activation of mast
cells in CFA-induced peripheral inflammation.
We also confirmed that CFA-induced mast cell degranula-
tion and paw edema occurred in WBB6F
 
1
 
-
 
W/W
 
v
 
 mice
reconstituted with either WT or NMU-KO BMMCs (Fig.
S2, available at http://www.jem.org/cgi/content/full/jem.
20050248/DC1). Thus, the lack of mast cell–mediated in-
flammation following CFA injection in NMU-KO mice re-
sults from the absence of NMU release, not from an intrinsic
defect in mast cell effector function. These results suggest that
NMU release from the environment after CFA treatment ac-
tivates mast cells. To identify potential sources of the neu-
ropeptide, we examined the localization of NMU in periph-
eral tissues by immunostaining. Specific recognition of NMU
Figure 2. NMU release from epidermis after intraplantar injection 
of CFA. After intraplantar injection of CFA, paws were isolated at the in-
dicated periods. Sections were stained with anti-NMU antiserum (top) or 
H&E (bottom). Bars, 100  m. 
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by our antibody was confirmed by a lack of significant reactiv-
ity in NMU-KO mice (Fig. 2).
In WT mice, intense NMU immunoreactivity was ob-
served in the epithelial layer of the hindpaw, suggesting that
keratinocytes may be a major source of this peptide. Intra-
plantar injection of CFA into the dermis induced a rapid re-
duction of NMU reactivity lasting up to 24 h. No destruc-
tion of the epithelial layers was observed. These data suggest
that NMU was released rapidly into the subcutaneous region
after CFA injection. Because mast cells are localized in close
proximity to the epithelial surface, expression of NMU in
epithelial tissues may ensure the immediate activation of
mast cells against environmental insults such as infection,
chemical damage, and mechanical and neurogenic stresses.
 
NMU promotes early inflammatory responses 
by mast cell activation
 
To investigate the induction of mast cell–dependent inflam-
matory responses by NMU in vivo, we injected NMU sub-
cutaneously into the paws of mice. SP, a potent neurogenic
inflammatory peptide, was used for comparison because it
has also been shown to induce degranulation of mast cells
(13). A single injection of NMU induced progressive vaso-
dilation in WT, NMU-KO, and WBB6F
 
1
 
-
 
 
 
/
 
 
 
 mice,
whereas NMU-induced vasodilation occurred only margin-
ally in WBB6F
 
1
 
-
 
W/W
 
v
 
 mice (Fig. 3 A). Measurement of
plasma extravasation using Evans blue outflow revealed that
NMU injection into WT and WBB6F
 
1
 
-
 
 
 
/
 
 
 
 mice, but not
into WBB6F
 
1
 
-
 
W/W
 
v
 
 mice, induced two- to threefold
higher extravasation than injection of vehicle (Fig. 3 B).
Subsequent paw edema was also observed in WT and
WBB6F
 
1
 
-
 
 
 
/
 
 
 
 mice, but not in WBB6F
 
1
 
-
 
W/W
 
v
 
 mice (Fig.
3 C). NMU induced these early inflammatory responses in
 
W/W
 
v
 
 -
 
 
 
/
 
 
 
 mice, in which BMMCs from WBB6F
 
1
 
-
 
 
 
/
 
 
 
mice were transferred adoptively into the paw (
 
W/W
 
v
 
 -
 
 
 
/
 
 
 
;
Fig. 3). These data indicate that NMU directly induces
mast cell–dependent responses, such as vasodilation, plasma
extravasation, and paw edema. In contrast to responses
induced by CFA injection, NMU induced responses in
NMU-KO mice similar to those seen in WT mice (KO; Fig.
Figure 3. Early mast cell-dependent inflammatory responses induced 
by NMU. (A) Vasodilation induced by NMU. 15 min after intraplantar 
injection of NMU into the indicated mice, paws were fixed and stained 
with H&E. Bars, 100  m. (B) Plasma extravasation 30 min after intraplantar 
injection of NMU or SP. (a) Representative hindpaws 30 min after the 
injection of NMU. (b) Quantification of Evans blue extravasation after in-
jection of indicated peptides or vehicle (n   4 for each group). *, P   0.05. 
(C) Changes in paw diameter 30 min after intraplantar injection of NMU or 
SP (n   4 for each group). *, P   0.05. 
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3). Thus, NMU-induced mast cell inflammation can occur
normally in NMU-KO mice, indicating that CFA-induced
mast cell–mediated inflammation in the paw is largely de-
pendent on the release of NMU in response to CFA.
In agreement with previous reports, SP injection into
hindpaw induced extravasation and paw swelling in the
hindpaws of WT, NMU-KO, and WBB6F1- /  mice, but
not in WBB6F1-W/Wv mice (Fig. 3 B b, and C, bottom).
Interestingly, plasma extravasation and paw edema induced
by SP were less intense than those after NMU injection.
Furthermore, the extravasation induced by SP was reduced
in NMU-KO mice from the levels observed in WT mice
(Fig. 3 B b, bottom), suggesting that SP-induced mast cell–
dependent extravasation may be dependent at least partially
on NMU. Further studies will be necessary to define the
functional relationship between NMU and SP.
We then examined whether NMU induces degranulation
of tissue mast cells in vivo (Fig. 4). NMU injection induced a
high level of degranulation of mast cells in WT and WBB6F1-
 /  mice as well as in NMU-KO mice (Fig. 4, A and C). The
number of paw mast cells was not significantly different among
WT, NMU-KO, and WBB6F1- /  mice irrespective of
NMU or SP injection (Fig. 4 B). Moreover, like WBB6F1- / 
mice, W/Wv - /  (Fig. 4 A) and W/Wv mice reconstituted
with WT BMMCs (W/Wv-WT; Fig. S3, available at http://
www.jem.org/cgi/content/full/jem.20050248/DC1) or with
NMU-KO BMMCs (W/Wv-KO; Fig. S3) showed NMU-
induced degranulation of mast cells and subsequent mast cell–
dependent inflammatory responses (Fig. S3 A).
These data indicate that NMU can activate mast cells
directly, leading to mast cell–dependent inflammation such
as vasodilation and edema.
SP injection into hindpaw also induced mast cell degran-
ulation in WT, NMU-KO, and WBB6F1- /  mice (SP;
Fig. 4, A and C). However, SP induced mast cell degranula-
tion at lower levels than NMU, which may account for
lower extravasation and paw swelling induced by SP than by
NMU (SP; Fig. 3, B b and C).
Direct activation of mast cells by NMU
Next, we examined the effects of NMU on mast cell func-
tion using peritoneal mast cells (PMCs) derived from WT
Figure 4. Degranulation of skin mast cells induced by NMU. (A) 15 
min after intraplantar injection of NMU (50 pmol) or SP (50 pmol) into WT, 
NMU-KO, and WBB6F1- /  mice, paws were stained with TB to detect 
mast cells. Bars, 50  m. (B) (a) Numbers of skin mast cells present in paws 
15 min after injection of saline, NMU, or SP. (b) Skin mast cells were 
classified into three categories by the degree of degranulation 15 min 
after injection of indicated peptides.NEUROMEDIN U PROMOTES MAST CELL–DEPENDENT INFLAMMATION | Moriyama et al. 222
mice. First, we confirmed the expression of NMU-R1 in
PMCs (Fig. 5 A). As shown in Fig. 5, B and C, NMU in-
duced Ca2  mobilization and degranulation of PMCs in a
dose-dependent manner. Ca2  mobilization and degranula-
tion of PMCs were observed at more than 10 4 M and 10 5 M
NMU, respectively. The levels of NMU-induced Ca2 
mobilization and degranulation of PMCs were almost com-
parable with those induced by IgE receptor cross-linking.
The low levels of IgE-dependent degranulation of PMCs
were probably observed because most IgE receptors on
PMCs were already occupied with endogenous IgE, as pre-
viously described (16); therefore, we speculate that only a
small percentage of IgE receptors are available to bind exog-
enous DNP-specific IgE.
In this study, we showed the expression of NMU-R1
in mast cells and demonstrated that NMU induces an early
inflammatory response by activating mast cells. Further-
more, the subsequent infiltration of neutrophils and expres-
sion of proinflammatory cytokines were completely sup-
pressed in NMU-KO mice. These data strongly support the
idea that NMU is the major mast cell–activating proinflam-
matory mediator produced in the periphery, especially in
the skin. It is interesting that a bioactive NMU peptide
(NMU-23) is secreted from frog skin (17); this observation
suggests that NMU is a highly conserved molecule func-
tioning in host defense against microbes, external mechani-
cal stresses, and injury.
The high expression of NMU in the dermal layer of the
skin contrasts with the expression patterns of other neu-
ropeptides, such as SP and neuropeptide Y, which are ex-
pressed primarily in neural cells and have been shown to be
involved in neurogenic inflammation. Although NMU is
involved in nociceptive transmission and appetite in the
nerve system (2, 6–8), our study demonstrated that NMU is
also involved in peripheral nonneurogenic inflammation
that activates mast cells. Thus, we speculate that NMU
functions as a link between neurogenic inflammatory stim-
uli and mast cell–mediated inflammation. In addition, the
effect of SP on neurogenic inflammation may require the
activation of NMU in the axonal reflex of the sensory path-
way. In either case, the blockade of NMU-R1 activation by
a specific antagonist in the periphery may be a novel strat-
egy to control the severity of inflammation in conditions
such as hyperalgesia.
Figure 5. NMU directly activates mast cells. (A) The levels of NMU and 
NMU-R1 mRNA in PMCs and the indicated organs were determined by 
RT-PCR. (B) Intracellular Ca2  mobilization after stimulation of PMCs with 
DNP-specific IgE, NMU, or SP. (Ba) Representative time course of intracellu-
lar Ca2  mobilization in Fluo-4-loaded PMCs. (Bb) Summary of the maxi-
mum intracellular Ca2  levels observed after stimulation with the indicated 
concentrations of DNP-specific IgE, NMU, or SP (n   3 for each point). (C) De-
granulation of PMCs was evaluated by the release of  -hexosaminidase into 
culture supernatants 30 min after stimulation with the indicated concentra-
tions of DNP-specific IgE, NMU, or SP (n   3 for each point).JEM VOL. 202, July 18, 2005 223
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MATERIALS AND METHODS
Experimental animals. NMU-KO mice were generated by gene target-
ing as described previously (14). NMU-KO mice were backcrossed more
than 10 times into a C57BL6/J background and compared with WT
C57BL6/J mice purchased from Japan CLEA. WBB6F1- /  and W/Wv
mice were purchased from Japan SLC, Inc. All animal procedures were per-
formed in accordance with the Japanese Physiological Society’s guidelines
for animal care.
Cutaneous inflammation. Skin inflammation was produced by intra-
plantar injection of 10  g CFA (in 20  l mineral oil, 50%; Sigma-Aldrich).
After measuring the CFA-induced paw edema with a micrometer, the hind-
paws were removed, immersed in 4% paraformaldehyde (PFA) solution, and
stained with hematoxylin and eosin (H&E). The Evans blue plasma extrava-
sation assay was performed as described (11). In brief, after anesthesia of the
mice, Evans blue (50 mg/kg) was injected intravenously into the jugular
vein. 50 pmol of SP or NMU (NMU-23; Peptide Institute, Inc.) was in-
jected into one hindpaw of the mouse, and the other paw was injected with
vehicle. After 30 min, the paw was removed, weighed, and incubated in
formamide for 24 h at 56 C. Extracted Evans blue was measured spectro-
photometrically at 600 nm. For the assessment of vasodilation and degranu-
lation of mast cells, hindpaws were removed 15 min after injection, fixed in
4% PFA, and stained with either H&E or TB.
Cell count and classification of skin mast cells. The number of skin
mast cells present at reaction sites was counted and expressed as the number
of cells/mm2 of dermis. Mast cells were classified into three categories: ex-
tensively granulated (50% of cytoplasmic granules exhibiting fusion), slightly
to moderately degranulated (10–15% of granules exhibiting fusion or dis-
charge), or normal as previously described (18).
RT-PCR analysis. For RT-PCR, total RNA was extracted using TRI-
zol reagent (Invitrogen). The synthesis of first-strand cDNA was performed
using SuperScript II (Invitrogen) according to the manufacturer’s instruc-
tions. The sequences of primer used are listed in Table S1.
Immunohistochemistry. NMU was detected as described (7). Briefly,
hindpaws of mice were immersed with 4% PFA overnight at 4 C and paraffin
sectioned to 5  m in thickness. Sections were incubated with rabbit anti–rat
NMU serum (donated by K. Mori, National Cardiovascular Center Research
Institute, Osaka, Japan) overnight at 4 C, then with Alexa Fluor 488 (Molecular
Probes, Inc.) diluted 1:200. Fluorescent images were obtained using a confocal
laser-scanning microscope (LSM 5 Pascal; Carl Zeiss MicroImaging, Inc.).
In vitro induction and reconstitution of WBB6F1-W/Wv mice with
BMMCs. BMMCs were maintained in RPMI 1640 supplemented with 5
ng/ml murine IL-3 (PeproTech), 8% FCS, 1% nonessential amino acids,
100 IU/ml penicillin, 100  g/ml streptomycin, and 10  M 2-mercaptoeth-
anol for 4–6 wk as described (19). For the reconstitution of skin mast cells
in WBB6F1-W/Wv mice, 106 BMMCs in 20  l of normal saline were in-
jected intradermally into the paws. 4 wk after injection of BMMCs, mice
were used for experiments.
Isolation and assays for peritoneal mast cells. Peritoneal mast cells
were isolated from Sprague-Dawley rats (250–300 g) as previously described
(20). For IgE-dependent activation of PMCs, cells were sensitized with var-
ious concentrations of DNP-specific IgE mAb (Sigma-Aldrich) for 1 h at
37 C before stimulation with 1  g/ml DNP-BSA. Ca2  mobilization assay
was performed as described (21) using Fluo-4-AM (Invitrogen) with FLEX-
station (Molecular Devices Corporation). Degranulation assay was per-
formed as described (13).
Statistics. Values are presented as mean   SE. Differences among groups
were analyzed using one-way analysis of variance with Scheffe’s post hoc
test. p-values  0.05 were considered to be significant.
Online supplemental material. Table S1 shows the specific primers
used for RT-PCR. Fig. S1 shows the number of skin mast cells and the
proportion of degranulation induced by CFA in WT, NMU-KO, and
WBB6F1- /  mice. Fig. S2 shows the CFA-induced inflammation and
degranulated mast cells in the paws of WBB6F1-W/Wv mice reconstituted
with BMMCs from WT and NMU-KO mice. Fig. S3 shows NMU-induced
vasodilation and degranulated mast cells in the paws of WBB6F1-W/Wv
mice reconstituted with BMMCs from WT and NMU-KO mice. Online
supplemental material is available at http://www.jem.org/cgi/content/full/
jem.20050248/DC1.
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